Public Companies
Evan Levine, CEO of PsyBio Therapeutics, Sits in the Investor Hotseat on October 13th
PsyBio Therapeutics ($PSYB) CEO, Evan Levine, joins the Investor Hotseat to field hot questions from host, Dustin Robinson of Iter Investments. Psybio…
PsyBio Therapeutics ($PSYB) CEO, Evan Levine, joins the Investor Hotseat to field hot questions from host, Dustin Robinson of Iter Investments.
Psybio has developed a portfolio of bio-medical chemistry development psycho-targeted compounds for the potential treatment for mental and neurological health.
Evan himself is a leader encompassing more than two decades of in-depth expertise in strategic ventures, executive supervision, asset management, and institutional investment businesses. He has served on the public and private boards of over a dozen companies in roles that include Chairman of the Board, Executive Chairman, Vice Chairman, Chief Executive Officer, Audit Committee Chairman, Nominating / Governance / Compensation Committee Member, and Trustee.
Will Evan be able to handle the heat in the hotseat?
As always, this will be a live event. You’ll be able to stream it from the Psychedelic Invest website, YouTube, LinkedIn, Facebook, Twitch, and Twitter. If you miss it, though, don’t worry. It will be recorded and available across those channels after the event.
If you’d like to attend the live event, you can set a reminder on Youtube or LinkedIn. Or, you can come back to the Hotseat livestream page at the time of the event.
To RSVP to ensure your spot, please fill out the form below.
A Transcription Will Be Available Following the Event
-
Psychedelics1 week ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Law & Regulation7 days ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics6 days ago
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
-
Psychedelics1 week ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics1 week ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Psychedelics6 days ago
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
-
Ketamine1 week ago
DEA poised to move cannabis to Schedule III
-
Psychedelics1 week ago
Are ‘Ketamine Bros’ Ruining It for Everyone Else?